Evolent Health Reports Massive Goodwill Impairment, Widened Losses, and Lower 2026 Profit Guidance

summarizeZusammenfassung

Evolent Health's latest earnings report reveals a deeply concerning financial picture. The company recorded a massive $398 million goodwill impairment in fiscal year 2025, which is larger than its current market capitalization, signaling a significant re-evaluation of its asset values and future prospects. This impairment contributed to a dramatic widening of the GAAP net loss to $(579.4) million from $(93.5) million in the prior year. Furthermore, revenue declined year-over-year. While the company projects approximately 30% revenue growth for 2026, its Adjusted EBITDA guidance of $110-$140 million is notably lower than the $151.2 million achieved in 2025. The CEO attributed the near-term Adjusted EBITDA impact to health plan customer membership decreases and new contract reserving effects, with an expectation for margins to improve by year-end 2026. However, the overall results and guidance present a challenging outlook, especially with the stock trading near its 52-week low. Investors should monitor the company's ability to execute on its cost reduction plan and achieve the projected margin step-up in the latter half of 2026.

check_boxSchlusselereignisse

• Massive Goodwill Impairment

  The company recorded a $398 million goodwill impairment in fiscal year 2025, a non-cash charge significantly impacting GAAP results.

• Widened Net Loss

  GAAP net loss attributable to common shareholders for FY2025 significantly widened to $(579.4) million, compared to $(93.5) million in FY2024.

• Revenue Decline

  FY2025 revenue decreased to $1.88 billion from $2.55 billion in FY2024.

• Lower 2026 Adjusted EBITDA Guidance

  The company provided 2026 Adjusted EBITDA guidance in the range of $110 million to $140 million, which is below the $151.2 million achieved in 2025.

auto_awesomeAnalyse

Evolent Health's latest earnings report reveals a deeply concerning financial picture. The company recorded a massive $398 million goodwill impairment in fiscal year 2025, which is larger than its current market capitalization, signaling a significant re-evaluation of its asset values and future prospects. This impairment contributed to a dramatic widening of the GAAP net loss to $(579.4) million from $(93.5) million in the prior year. Furthermore, revenue declined year-over-year. While the company projects approximately 30% revenue growth for 2026, its Adjusted EBITDA guidance of $110-$140 million is notably lower than the $151.2 million achieved in 2025. The CEO attributed the near-term Adjusted EBITDA impact to health plan customer membership decreases and new contract reserving effects, with an expectation for margins to improve by year-end 2026. However, the overall results and guidance present a challenging outlook, especially with the stock trading near its 52-week low. Investors should monitor the company's ability to execute on its cost reduction plan and achieve the projected margin step-up in the latter half of 2026.